Oxford Covid vaccine: Phase 3 trials to end by Nov

Aurobindo Pharma has said it is expecting its proposed vaccine candidate for Covid-19 to undergo phase-1 and 2 trials by the end of 2020, while Phase III may be undertaken during March-April next year.

Managing Director Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major had earmarked $150-200 million towards capital expenditure during the current fiscal year.

He said the vaccine for Covid-19 was being developed by Profectus BioSciences in the US, which was acquired by Aurobindo Pharma’s subsidiary Auro Vaccines LLC.